Neoplasms

3,880 trials 1,551 recruiting

Filter these 3,880 trials by phase, country and sponsor.

Open in Search →

Prognostic value of early assessment by ⁶⁸Ga-DOTATATE PET/CT for the treatment of well-differentiated grade 2 gastroenteropancreatic neuroen… Pending

2025-524942-87-00 Gastroenteropancreatic neuroendocrine tumors 6
A study to investigate WEF-001 in patients with Advanced KRAS-Mutant Solid Tumours. Pending

2024-518644-21-01 Advanced KRAS- Mutant Solid Tumours 9
Study on the feasibility of fluorescence bronchoscopy with bevacizumab-800CW - DEFLECT I Pending

2024-510793-24-00 suspected malignant pulmonary disease (lung lesions and 4
Repurposed Drugs in Research and Cancer Clinical Trials. The ReDiReCCT trial Vemurafenib Pending

2025-523340-12-00 Glioma 3
Ironstomach Pending

2024-519738-21-01 Patients with gastric cancer 6
MITO CERV4: Single arm phase II study on Pembrolizumab in pre neoplastic high grade HPV-related vulvar and cervical lesions Pending

2023-504035-40-00 Patients with pre neoplastic high grade HPV-related vul 4
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable high grade gliomas patients Pending

2024-514144-85-02 Glioblastoma 3
A study to investigate efficacy of RP2 with nivolumab compared to ipilimumab with nivolumab in adult patients with advanced uveal melanoma n… Pending

2023-508784-68-00 metastatic uveal melanoma 10
A Phase 1 Study of TORL-1-23 in Advanced Cancer Pending

2024-517189-40-00 Advanced Cancer 1
Receptor radionuclide therapy with 177Lu-DOTATOC (177Lu- edotreotide or 177Lu-octreotide) in SSTR positive patients: a multicenter, prospect… Pending

2024-519183-40-00 NET 4
Maintenance AVElumab after SECond line platinum-based chemotherapy for metastatic urothelial carcinoma: AVESEC trial – GOIRC-02-2025 Pending

2025-524077-16-00 metastatic urothelial carcinoma 4
NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing sacituzumab govitecan+pembrolizumab vs. SoC chemotherapy in clinical st… Pending

2024-516734-35-00 triple-negative early breast cancer 5
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic P… Pending

2025-525009-18-00 Pancreatic Ductal Adenocarcinoma 5
A Biomarker-Directed, Multi-Centre Phase II/III Study of ctDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer - BR.36 Pending

2025-522084-15-00 metastatic NSCLC patients 10
A Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer. Pending

2025-525013-23-00 Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC) 4
Clinical trial of selinexor plus gemcitabine in selected advanced soft-tissue sarcomas Pending

2024-520318-23-00 Patients with advanced soft-tissue sarcoma (leiomyosarc 9
METAREM / META-1 - METAREM :Immunotherapy Master Trial for Advanced Cancers / META-1: Immunotherapy without chemotherapy for advanced lung c… Pending

2025-522655-26-00 METAREM:Patients with advanced cancer, as defined as un 4
Neo-adjuvant intraperitoneal chemotherapy (irinotecan) and systemic chemotherapy (mFOLFOX4-bevacizumab) prior to CRS-HIPEC for patients with… Pending

2024-512318-16-00 Patients with colorectal peritoneal metastases with a P 4
OVACURE-2 Pending

2025-522659-24-00 Ovarian carcinoma 9
SAKK 38/19: Assessing a ctDNA and PET-oriented therapy in patients with DLBCL. A multicenter, open-label, phase II trial Pending

2024-516740-26-00 Disseminated large B-cell lymphoma 4
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ… Pending

2025-524095-27-00 HER2-negative, unresectable, recurrent, and/or metastat 4
Phase I clinical trial evaluating TG4070 in patients with non-small cell lung cancer Pending

2025-520946-31-00 Non-Small Cell Lung Cancer 1
SIOP PNET 5 medulloblastoma Pending

2024-513724-42-00 Medulloblastoma 10
Pulmonary Embolism & Anticoagulation Evaluation in Cancer Patient - PEACE Pending

2025-524110-28-00 Incidental Subsegmental Pulmonary Embolism in cancer pa 6